Varivax is a live-attenuated virus vaccine used to prevent chickenpox (varicella) caused by the Varicella-zoster virus.

Benefits of VARIVAX
This vaccine helps prevent chickenpox (varicella) caused by the varicella virus, which is transmitted through saliva droplets or direct contact with the lesions or rashes of an infected person.

The infectious period occurs from 2 days before the rash appears until all lesions have dried. Early symptoms include fever, fatigue, itching, followed by the appearance of raised red spots or rashes that usually start on the face and scalp and may spread to other parts of the body.

Chickenpox can lead to severe skin infections, scarring, pneumonia, encephalitis (brain inflammation), and Reye syndrome.

Composition of VARIVAX
Children
Ages 1–12 years: 2 doses with an interval of 6 weeks to 3 months
Ages >13 years: 2 doses with an interval of 4–6 weeks

Adults:
2 doses with an interval of 4–6 weeks
Elderly:
2 doses with an interval of 4–6 weeks

Composition of VARIVAX
Each 0.5 ml dose contains: Live attenuated varicella virus

Contraindication of VARIVAX
• Varicella-like skin rash
• Fever
• Swelling and redness at the injection site